Niagen Bioscience (OCD1) Q3 2026 Earnings Report

The call was broadly constructive, supported by positive operating cash flow, a debt-free balance sheet, resilient direct-to-consumer demand, expanded distribution, progress in skincare and Niagen Plus, and advancing pharmaceutical and scientific programs. These positives were tempered by a 10% year-over-year decline in Tru Niagen revenue, increased competition, a 160 basis point gross-margin decline, a quarterly net loss and higher expected spending.

Niagen Bioscience said each business is well positioned for significant growth in 2027, expects fourth quarter revenue to improve sequentially from the third quarter, expects to begin commercialization of a new NR salt form in early 2027, expects a topical product incorporating Niagen to reach the market in early 2027, plans to launch a new branded skin care product in the first half of 2027, and plans to begin first-in-human studies of NB4168 in 2027, subject to completion of the necessary development work and regulatory clearance; the company is presently thinking about 5,000 participants and a 3-year term for the Mass General Brigham prevention trial, expects China cross-border sales to be more than 2 to 3x compared to last year, expects malate to reduce cost of goods in some way in 2027 and in a significant way after that, and expects increased selling and marketing expenses, R&D investments and G&A spending.